Discontinuation of Hypomethylating Agent Therapy in Patients with Myelodysplastic Syndromes or Acute Myelogenous Leukemia in Complete Remission or Partial Response: Retrospective Analysis of Survival after Long-term Follow-up

Hypomethylating agents (HMA), such as 5-azacitidine or decitabine, are currently used to treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) until treatment failure. However, the outcomes for patients who discontinue therapy after achieving partial response (PR) or co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leuk Res
Hauptverfasser: Cabrero, Monica, Jabbour, Elias, Ravandi, Farhad, Bohannan, Zach, Pierce, Sherry, Kantarjian, Hagop M., Garcia-Manero, Guillermo
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826042/
https://ncbi.nlm.nih.gov/pubmed/25828745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.03.006
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge